Skip to main content
. Author manuscript; available in PMC: 2020 Apr 15.
Published in final edited form as: Clin Cancer Res. 2019 Jul 29;25(20):6044–6051. doi: 10.1158/1078-0432.CCR-19-0798

Table 5:

Development of anti-hu14.18-IL2 antibody in relation to response

Test Factor N Number of responders p-value
Anti-IC Negative
Positive or intermediate		 14
12		 2 (14.3%)
3 (25.0%)		 0.6348
Anti-IC Negative
Positive		 14
5		 2 (14.3%)
1 (20.0%)		 1.0000
Anti-IC Negative or Intermediate
Positive		 21
5		 4 (19.0%)
1 (20.0%)		 1.0000

The peak anti-IC level for each of 26 patients evaluable for response with serum available by bridging-ELISA method was characterized as: negative (<0.5 OD); intermediate (0.5 −2.0 OD); or positive (>2.0 OD).